Gedatolisib Combo Approved for Advanced Breast Cancer

Published Date: 17 Jul 2026

Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.

Read Full News

Latest News

Race, Geography Linked to Gaps in Prostate Cancer Care

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Community Oncology Well Suited for Advanced Cancer Patients

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Todays Updates

Body Clock Genes Tied to Prostate Radiotherapy Toxicity

Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?

MGRS Relapse-Free Survival Better With Maintenance Therapy

Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.

Todays Updates

Body Clock Genes Tied to Prostate Radiotherapy Toxicity

Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?

MGRS Relapse-Free Survival Better With Maintenance Therapy

Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.

Latest News

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

News All Time

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Is There a Role for Stimulants in Beating Cancer Fatigue?

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Combination Treatment May Improve Multiple Myeloma Outcomes

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

Inside the Major Findings From the NHS-Galleri Trial

The largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Pain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.

The Growing Role of AI in Cancer Treatment

Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.

Capivasertib Wins Metastatic Prostate Cancer Approval

The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Recommended News For You

Medical debt in collections persists after cancer diagnosis

Early, virtual palliative care feasible for advanced lung cancer

Year in Review: Chronic Lymphocytic Leukemia

Psychiatric Disorders Are Common in Dementia Patients.

Remote monitoring can improve recovery from cancer surgery

Researchers discover cellular 'doorway' exploited by cancer-causing virus

Abemaciclib Slows Progression of Advanced Liposarcoma

Recommended Articles For You

Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy 

Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia 

Tumor Microenvironment Targeting: Mechanisms, Clinical Implications, and Therapeutic Advances 

Advanced Directions in Oncology and Quality Improvement 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

2.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

3.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

4.

Oncology Drug Shortages Persist, but Continue to Evolve

5.

Are patients with advanced cancer receiving treatment aligned with their goals?

1.

Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization

2.

Hematopoietic Aging Signatures and Future Hematologic Disease Risk

3.

Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025

4.

Clinical Frameworks in Oncology and Quality Improvement

5.

Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

3.

Efficient Management of First line ALK-rearranged NSCLC - Part II

4.

Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot